The Role of Glia in Alpha-Synucleinopathies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
α-Synuclein (AS)-positive inclusions are the pathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), all belonging to the category of α-synucleinopathies. α-Synucleinopathies represent progressive neurodegenerative disorders characterised by increasing incidences in the population over the age of 65. The relevance of glial reactivity and dysfunction in α-synucleinopathies is highlighted by numerous experimental evidences. Glial AS inclusion pathology is prominent in oligodendroglia of MSA (glial cytoplasmic inclusions) and is a common finding in astroglial cells of PD and DLB, resulting in specific dysfunctional responses. Involvement of AS-dependent astroglial and microglial activation in neurodegenerative mechanisms, and therefore in disease initiation and progression, has been suggested. The aim of this review is to summarise and discuss the multifaceted responses of glial cells in α-synucleinopathies. The beneficial, as well as detrimental, effects of glial cells on neuronal viability are taken into consideration to draw an integrated picture of glial roles in α-synucleinopathies. Furthermore, an overview on therapeutic approaches outlines the difficulties of translating promising experimental studies into successful clinical trials targeting candidate glial pathomechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485 · cited 2×
“Moreover, prion-like cell-to-cell propagation of AS has been proposed recently as a major contributor to disease progression in α-synucleinopathies [21–23].”
BackgroundZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 5×
“neurodegeneration and neuronal cell death [84].”
BackgroundInfluentialIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 2×
“In PD, different studies report an accumulation of reactive microglia around AS-positive LBs using in vivo imaging techniques [28] or post-mortem brain analysis [53,71].”
BackgroundWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., & Vekrellis, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5699-09.2010 · Cited by 1,115
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 4×
“positive inclusions in astroglial cells in PD brains was provided by Lee and colleagues [23].”
BackgroundMethodInfluentialHansen, C., Angot, E., Bergström, A.-L., Steiner, J. A., Pieri, L., Paul, G., Outeiro, T. F., Melki, R., Kallunki, P., Fog, K., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43366 · Cited by 842
α-Synuclein impairs macroautophagy: implications for Parkinson’s disease
Winslow, A. R., Chen, C.-W., Corrochano, S., Acevedo-Arozena, A., Gordon, D. E., Peden, A. A., Lichtenberg, M., Menzies, F. M., Ravikumar, B., Imarisio, S., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201003122 · Cited by 825
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“Microglial activation is shown in different brain regions of PD end-stage cases, including SN, putamen, hippocampus, transentorhinal, cingulated and temporal cortex [72], in all areas of the limbic system, in particular, the dentate gyrus and the CA2/3 region of the”
BackgroundHDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508786200 · Cited by 719 · cited 1×
“aggresomes [127] and aggresome degradation [128] as well as the control of autophagy pathways [129], and its accumulation”
BackgroundWilhelmsson, U., Bushong, E. A., Price, D. L., Smarr, B. L., Phung, V., Terada, M., Ellisman, M. H., & Pekny, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602841103 · Cited by 643 · cited 2×
“microglia, also clearance of dead or damaged cells [30–34].”
BackgroundSchulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542 · cited 1×
“neuroprotection, as well as reduced AS inclusion pathology [161].”
BackgroundParkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., et al. (2011) · Nature Communications · doi:10.1038/ncomms1453 · Cited by 486
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 1×
“Cell culture models demonstrated that microglialconditioned release of pro-inflammatory cytokines upon AS treatment was dose-dependent [76,78].”
BackgroundPro‐regenerative properties of cytokine‐activated astrocytes
Liberto, C. M., Albrecht, P. J., Herx, L. M., Yong, V. W., & Levison, S. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02420.x · Cited by 464
Braak, H., Sastre, M., & Del Tredici, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0244-3 · Cited by 462
Thorburne, S. K., & Juurlink, B. H. J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67031014.x · Cited by 390
Papp, M. I., & Lantos, P. L. (1994) · Brain · doi:10.1093/brain/117.2.235 · Cited by 389 · cited 2×
“[3,102–104].”
BackgroundGao, H.-M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., & Hong, J.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3732-10.2011 · Cited by 369 · cited 1×
“Moreover, different strategies on the inhibition of micro- and astroglial activation were followed in various experimental approaches leading to neuroprotection, including iNOS and NADPH oxidase inhibition [140,141], suppression of the peroxisome proliferator-activated receptor 580 Mol Neurobiol (2013) 47:575–586”
MethodClearance and deposition of extracellular α-synuclein aggregates in microglia
Lee, H.-J., Suk, J.-E., Bae, E.-J., & Lee, S.-J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.045 · Cited by 343 · cited 2×
“On the one hand, microglial cells recognise extracellular AS released by damaged neurons; moreover, they are crucial in the clearance of this protein [86,87].”
BackgroundThe role of glial cells in Parkinsonʼs disease
Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326
Yazawa, I., Giasson, B. I., Sasaki, R., Zhang, B., Joyce, S., Uryu, K., Trojanowski, J. Q., & Lee, V. M.-Y. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.032 · Cited by 301
Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons
Stefanova, N., Fellner, L., Reindl, M., Masliah, E., Poewe, W., & Wenning, G. K. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.04.013 · Cited by 272
Self-citationSanchez-Guajardo, V., Febbraro, F., Kirik, D., & Romero-Ramos, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008784 · Cited by 256 · cited 1×
“AS expression [79].”
Shults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3527-05.2005 · Cited by 254 · cited 2×
“mitochondrial dysfunction [109,112,134].”
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227 · cited 3×
“release of pro-inflammatory agents [76,82], increases oxidative stress through the release of ROS [84] and may be of”
BackgroundStefanova, N., Reindl, M., Neumann, M., Haass, C., Poewe, W., Kahle, P. J., & Wenning, G. K. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62307-3 · Cited by 208 · cited 3×
“cells [110].”
BackgroundSelf-citationAbsence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia
Miller, D. W., Johnson, J. M., Solano, S. M., Hollingsworth, Z. R., Standaert, D. G., & Young, A. B. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0378-1 · Cited by 198 · cited 1×
“oligodendroglial cells ofMSA brains [113,121].”
Microglial Activation Parallels System Degeneration in Multiple System Atrophy
Ishizawa, K., Komori, T., Sasaki, S., Arai, N., Mizutani, T., & Hirose, T. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.1.43 · Cited by 172
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162
Self-citationUbhi, K., Rockenstein, E., Mante, M., Inglis, C., Adame, A., Patrick, C., Whitney, K., & Masliah, E. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0567-10.2010 · Cited by 147 · cited 1×
“trophic support of neurons [135].”
Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity
Su, X., Federoff, H. J., & Maguire-Zeiss, K. A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9053-x · Cited by 145
Stefanova, N., Georgievska, B., Eriksson, H., Poewe, W., & Wenning, G. K. (2012) · Neurotoxicity Research · doi:10.1007/s12640-011-9294-3 · Cited by 111
Self-citationExpression of mutant alpha-synuclein modulates microglial phenotype in vitro
Rojanathammanee, L., Murphy, E. J., & Combs, C. K. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-44 · Cited by 106 · cited 1×
“Furthermore, mutant ASoverexpressing BV2 cells produced an increased amount of NO [83].”
BackgroundGlial cell death induced by overexpression of α‐synuclein
Stefanova, N., Klimaschewski, L., Poewe, W., Wenning, G. K., & Reindl, M. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1171 · Cited by 93
Self-citationStemberger, S., Poewe, W., Wenning, G. K., & Stefanova, N. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.008 · Cited by 83
Self-citation
Cited by
Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease
Guo, M., Wang, J., Zhao, Y., Feng, Y., Han, S., Dong, Q., Cui, M., & Tieu, K. (2020) · Brain · doi:10.1093/brain/awaa090 · Cited by 522
The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies
Seidel, K., Mahlke, J., Siswanto, S., Krüger, R., Heinsen, H., Auburger, G., Bouzrou, M., Grinberg, L. T., Wicht, H., Korf, H., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12168 · Cited by 306
The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Rui, Q., Ni, H., Li, D., Gao, R., & Chen, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180222165418 · Cited by 196
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132
Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?
Spampinato, S. F., Copani, A., Nicoletti, F., Sortino, M. A., & Caraci, F. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00414 · Cited by 105
“Oligodendrocyte dysfunction is mainly involved in the pathogenesis of classical demyelinating diseases (MS and NMO) and leukodystrophies (Fellner and Stefanova, 2013; Ettle et al., 2016).”
Background
Metadata
- Authors
- Fellner, L., & Stefanova, N.
- Venue
- Molecular Neurobiology
- Published
- 2012-09-02
- Volume
- 47
- Issue
- 2
- Pages
- 575-586
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2089874656
- Cited by
- 68
- References
- 40
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.